Neurogene Inc.·4

Nov 25, 9:29 PM ET

McMinn Rachel 4

4 · Neurogene Inc. · Filed Nov 25, 2024

Insider Transaction Report

Form 4
Period: 2024-11-22
McMinn Rachel
DirectorChief Executive Officer
Transactions
  • Purchase

    Common Stock

    2024-11-22$20.40/sh+47,500$969,0001,297,859 total
Footnotes (1)
  • [F1]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.07 to $20.84, inclusive. The reporting person undertakes to provide to Neurogene Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Documents

1 file
  • 4
    wk-form4_1732588138.xmlPrimary

    FORM 4